- Imagion Biosystems (IBX) has requested two consecutive trading halts pending a capital raise
- The healthcare company will remain in the halt until July 31 or when the announcement is made, whichever occurs first
- On July 22, Imagion’s annual general meeting was held online due to COVID-19
- A key point of discussion was the company’s MagSense diagnostic imaging technology, with Imagion currently in the progress of planning a phase one study
- MagSense uses disease-specific targeting nanoparticles and highly sensitive detectors to find tumours and other diseased cells
- Further, the company also announced it would work with Boston University on the next generation of imaging technology
- Shares in Imagion last traded for six cents each on July 23
Imagion Biosystems (IBX) has requested two consecutive trading halts pending a capital raise.
The healthcare company will remain in the halt until July 31 or when the announcement is made, whichever occurs first.
On July 22, Imagion’s annual general meeting was held online due to COVID-19.
A key point of discussion was the company’s MagSense diagnostic imaging technology, with Imagion currently in the progress of planning a phase one study to determine its safety.
MagSense uses disease-specific targeting nanoparticles and highly sensitive detectors to find tumours and other diseased cells.
According to Imagion, it doesn’t use radiation, instead dispatching tiny bio-safe nanoparticles coated with tumour-targeting antibodies.
Further, two weeks ago Imagion announced it would work with Boston University on the next generation of imaging technology.
This partnership will aim to develop ultrasensitive magnetic sensors that could simplify MagSense, and, if successful, MagSense could potentially be used as a hand-held technology.
Finally, the company’s Chief Financial Officer Brian Conn is leaving to take on another full-time role.
Shares in Imagion last traded for six cents each on July 23.